KDR and cancer: Some of the synthesized agents revealed promising antiproliferation activity (MTT assay) against the A549 (NSCLC), MCF7 (breast) and HT-29 (colon) cancer cell lines with enzymatic inhibitory properties against VEGFR-2 and PDGFR-β (ESI Fig. S10†).